Nucs AI Introduces TrackPSMA for Enhanced Prostate Cancer Management
More than half of prostate cancer patients on radioligand therapy may face the risk of non-response. With this in mind, Nucs AI takes a significant step forward in treatment monitoring with the launch of TrackPSMA. This pioneering platform employs artificial intelligence to assist physicians in assessing treatment effectiveness and directing patients toward the most suitable care options.
Understanding the Challenges of Radioligand Therapy
Radioligand therapy has emerged as a formidable potential treatment for prostate cancer, but it comes with its challenges. There is an ongoing need to determine which patients will respond favorably and to establish dependable methods to evaluate treatment response. Studies reveal that up to 54% of patients undergoing therapy may not see any benefits, indicating urgency in identifying suitable candidates for alternative treatments. For those who do benefit, precise, quantitative insights offer a way to customize their treatment to maximize positive outcomes while reducing unnecessary exposure to ineffective therapies.
The Role of TrackPSMA in Treatment Assessment
TrackPSMA revolutionizes the way treatment responses are evaluated by providing a fast and quantitative assessment of PSMA-PET/CT scans over time. This tool aids physicians in closely monitoring patient responses to treatment and facilitates timely adjustments to optimize care, whether that involves altering dosages or switching to more effective therapies.
Improved Tracking and Standardization
Through TrackPSMA, the ability to quantify changes in disease status—derived from both initial screening and follow-up scans—has improved remarkably. Traditional assessment methods were frequently unstructured and relied on subjective visual examinations. Now, with lesion-by-lesion tracking, doctors can analyze individual lesions over time, leading to data-driven, standardized assessments that are available in seconds. This newfound speed and accuracy provide physicians with the confidence needed to make more informed decisions regarding treatment plans.
Expert Insights on TrackPSMA’s Impact
“Measuring disease progression for each lesion is a groundbreaking change in how we manage cancer,” stated Farid Yagubbayli, CTO of Nucs AI. “This advancement transitions us from subjective visual inspections to a systematic, data-driven evaluation which supports quicker and more accurate interventions.”
Nijat Ahmadov, CEO of Nucs AI, elaborated that, “TrackPSMA signifies a pivotal enhancement in the application of AI for treatment planning. By delivering swift, standardized evaluations of treatment responses, we are paving the way for physicians and pharmaceutical companies to better comprehend which treatments are truly effective for individual patients.”
The Broader Vision of Nucs AI
The unveiling of TrackPSMA represents another significant milestone in Nucs AI's vision to reshape the role of AI within medical imaging. With ongoing partnerships with esteemed institutions like Johns Hopkins, Nucs AI seeks to expand its portfolio and fulfill the growing global demand for AI-driven radiology solutions. Attendees of the RSNA 2025 can visit Nucs AI’s booth to learn how this innovative company is enhancing evidence-based evaluations of next-generation treatments for prostate cancer.
About Nucs AI
Nucs AI is at the forefront of transforming precision radiology through its AI-powered imaging and predictive analytics solutions. Its product line—including DeepPSMA, SelectPSMA, and the innovative TrackPSMA—automates numerous processes from detection to evaluation of treatment responses, ensuring clinicians can make faster and more informed decisions for their patients. With established global partnerships including Johns Hopkins and other leading institutions, Nucs AI is setting new benchmarks in molecular imaging and AI-assisted diagnostics, significantly influencing the future of healthcare.
Frequently Asked Questions
What is TrackPSMA?
TrackPSMA is a new AI tool from Nucs AI that helps doctors evaluate treatment responses in prostate cancer patients faster and more accurately.
How does TrackPSMA work?
It analyzes PSMA-PET/CT scans over time to monitor changes in treatment response and helps physicians make timely adjustments to optimize patient care.
Why is tracking treatment response important?
Early identification of treatment effectiveness can prevent unnecessary exposure to ineffective therapies and allow for more personalized treatment options.
What advancements does TrackPSMA offer compared to traditional methods?
TrackPSMA provides a standardized and objective evaluation of treatment response, eliminating the inconsistencies of subjective visual assessments that were previously common.
Is Nucs AI involved in collaborations?
Yes, Nucs AI collaborates with several leading institutions, including Johns Hopkins, to advance its AI solutions in medical imaging.
